Effect of Conjugated Linoleic Acid supplemented diet on oxidative stress in Chronic Obstructive Pulmonary Disease

Effect of Conjugated linoleic acid supplemented diet on nutritional status, and oxidative stress in Chronic Obstructive Pulmonary Disease patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015080823559N1

Enrollment

Registered

2015-09-27

Start date

2015-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease. Chronic Lower Respiratory Diseases

Interventions

Intervention 1: treatment intentervention with conjugated linoleic acid 3.2 g(soft gel 800mg four times in day) for six weeks. Intervention 2: Placebo soft gel four times in day for six weeks.

Treatment - Drugs

Placebo

treatment intentervention with conjugated linoleic acid 3.2 g(soft gel 800mg four times in day) for six weeks

Placebo soft gel four times in day for six weeks

Eligibility

Sex/Gender

Male

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Chronic Obstructive Pulmonary Disease patients aged between 40-80? clinically stable disease with FEV1 less than 75% predict. Exclusion criteria:female? any associated diseases such as CAD and CKD ..? receiving any interacting drugs? abnormal chest x ray

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Malondialdehyde (MDA) serum level. Timepoint: At the beginning of study and 6 weeks after intervention. Method of measurement: Lab.;IL1ß serum level. Timepoint: At the beginning of study and 6 weeks after intervention. Method of measurement: Lab.;Total Antioxidan Capacity. Timepoint: At the beginning of study and 6 weeks after intervention. Method of measurement: Lab.;Matrix metallopeptidase 1 serum level(MMP1). Timepoint: At the beginning of study and 6 weeks after intervention. Method of measurement: Lab.;Matrix metallopeptidase 2 (MMP2) serum level. Timepoint: At the beginning of study and 6 weeks after intervention. Method of measurement: Lab.;Leptin serum level. Timepoint: At the beginning of study and 6 weeks after intervention. Method of measurement: Lab.;Added at 2017-11-01: Sirtuin 1. Timepoint: Added at 2017-11-01: before and after intervention. Method of measurement: Added at 2017-11-01: ELISA.;Added at 2017-11-01: Interleukin 6. Timepoint: Added at 2017-11-01: At the beginning of study and 6 weeks after intervention. Method of measurement: Added at 2017-11-01: Lab.	—

Measure

Time frame

Malondialdehyde (MDA) serum level. Timepoint: At the beginning of study and 6 weeks after intervention. Method of measurement: Lab.;IL1ß serum level. Timepoint: At the beginning of study and 6 weeks after intervention. Method of measurement: Lab.;Total Antioxidan Capacity. Timepoint: At the beginning of study and 6 weeks after intervention. Method of measurement: Lab.;Matrix metallopeptidase 1 serum level(MMP1). Timepoint: At the beginning of study and 6 weeks after intervention. Method of measurement: Lab.;Matrix metallopeptidase 2 (MMP2) serum level. Timepoint: At the beginning of study and 6 weeks after intervention. Method of measurement: Lab.;Leptin serum level. Timepoint: At the beginning of study and 6 weeks after intervention. Method of measurement: Lab.;Added at 2017-11-01: Sirtuin 1. Timepoint: Added at 2017-11-01: before and after intervention. Method of measurement: Added at 2017-11-01: ELISA.;Added at 2017-11-01: Interleukin 6. Timepoint: Added at 2017-11-01: At the beginning of study and 6 weeks after intervention. Method of measurement: Added at 2017-11-01: Lab.

—

Secondary

Measure	Time frame
CLA side effects. Timepoint: At the beginning of study and 6 weeks after intervention. Method of measurement: patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomaieh Matin

Ardabil University of Medical Sciences

s.matin@arums.ac.ir+98 45 3373 3011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026